- ISRAEL21c - http://www.israel21c.org -
Israeli biotech Macrocure sets terms for $75 million IPO
Posted By Viva Sarah Press On July 28, 2014 @ 5:08 am In | No Comments
Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal and chronic wounds, has announced terms for its $75 million IPO. The Petach Tikva company is offering 5.4 million shares, according to Renaissance Capital Investments.
Macrocure’s main product is CureXcell, a cell based therapy that when applied to a wound, restores the natural balance required for the wound healing process.
CureXcell has been approved as a medical device in Israel and has been used in more than 5,000 patients in commercial or clinical study settings with consistent results, according to Macrocure data.
Article printed from ISRAEL21c: http://www.israel21c.org
URL to article: http://www.israel21c.org/news/israeli-biotech-macrocure-sets-terms-for-75-million-ipo/
Copyright © 2012 Israel. All rights reserved.